Commentary|Videos|October 29, 2024
Lorlatinib in ROS1+ Advanced NSCLC After Crizotinib and Chemotherapy
Author(s)Benjamin Besse, MD, Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Advertisement
Episodes in this series
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Advertisement
Related to this article
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
5